Clinical trial
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
NCT00035295 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00035295 |
|---|---|
| Title | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) |
| Official title | A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | MK0869, aprepitant, Comparator: placebo |
| Enrollment | 584 |
| Start date | Nov 8, 2001 |
| Primary completion | Dec 5, 2003 |
| Completion | Dec 5, 2003 |
| First posted | May 3, 2002 |
| Last update posted | Apr 18, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: